Peptide Comparison
CJC-1295 vs Hexarelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
CJC-1295 and Hexarelin share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Phase 2 (not approved)). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| CJC-1295 | Hexarelin | |
|---|---|---|
| Class | GHRH analog (no-DAC or DAC forms) | GHRP; potent ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life | GHS-R1a agonist; more potent GH release than other GHRPs |
| Route | SC injection | SC / Intranasal |
| Half-life | No-DAC ~30 min / DAC ~8 days | ~1 hr |
| Dosage (research) | No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) | 100-200 mcg SC 1-2x daily (short cycles) |
| Evidence tier | Anecdotal + Phase 2 (DAC) | Phase 2 (not approved) |
| Research depth | 44 indexed | 158 indexed |
| Availability | Compounding Restricted | Research Chemical |
| Reported risks | Water retention; numbness/tingling; elevated IGF-1; injection site reactions | Cortisol/prolactin elevation; pituitary desensitization |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 or Hexarelin?
CJC-1295 and Hexarelin share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Phase 2 (not approved)). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.
What is the difference between CJC-1295 and Hexarelin?
CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; Hexarelin, ~1 hr. Routes in published studies: CJC-1295, SC injection; Hexarelin, SC / Intranasal.
Which has stronger evidence, CJC-1295 or Hexarelin?
CJC-1295 and Hexarelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies.
Which is more accessible, CJC-1295 or Hexarelin?
Neither CJC-1295 nor Hexarelin is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; Hexarelin, Research Chemical. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are CJC-1295 and Hexarelin ever combined?
CJC-1295 and Hexarelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…